Benefit of infusions with ibandronate treatment in children with osteogenesis imperfecta
- Author:
- No author available
- Journal Title:
- Chinese Medical Journal
- Issue:
- 19
- DOI:
- 10.3760/cma.j.issn.0366-6999.2011.19.017
- Key Word:
- osteogenesis imperfecta;ibandronate;annual new fracture rate;bone mineral density
Abstract： Background Osteogenesis imperfecta (OI) is a rare bone disease and its effective treatment is relatively deficient. We tried to assess the effects of new bisphosphonate, ibandronate on children with OI.Methods In this open-label, prospective, controlled study, 30 children with OI were enrolled. They received either infusions of ibandronate (2 mg) in every three months or oral calcitriol 0.25 μg daily for 24 months. All patients took 500 mg calcium plus 200 U vitamin D daily together. The endpoints were the change of annual new fracture rate (observed by case history and X ray films of spine), bone mineral density (BMD, measured by dual energy X-ray absortiometry), serum concentration of carboxy-telopeptide cross-links of type Ⅰ collagen (CTX, bone resorption marker) and alkaline phosphatase (ALP, bone formation marker) during the follow-up.Results After the cyclic infusions of ibandronate, the annual new fracture rate was significantly decreased from 1.9 to 0.13 time, obviously lower than that of calcitriol group, which decreased from 1.8 to 1.0 time after the treatment (P ＜0.001).The significant increase of BMD at the lumbar spine, femoral neck, trochanter, total hip was found in the group of ibandronate by 59.0％, 42.0％, 47.5％ and 36.6％ in time dependent manner (compared with the baseline, P ＜0.001). The increase of BMD in ibandronate group was greater than that of calcitriol group (P ＜0.001). The concentrations of ALP and CTX were obviously decreased in ibandronate group, and the reduction of CTX was more significant than that of ALP (P ＜0.001). The tolerance of the children to ibandronate was quite well. Mild fever and muscle pain were found in 9 cases within 1-3 days after the first infusion of ibandronate, which could relieve after 1-2 days without special management.Conclusions The benefits of cyclic infusions of ibandronate to children with OI are significant because ibandronate could significantly reduce annual bone fracture rate, increase lumbar and hip BMD, preserve vertebral morphometry of patients through inhibition of bone resorption.
- [1]Robert A, Adler.Glucocorticoid-induced osteoporosis: management update.[J].2010,8(1).
- [2]F.S. Van Dijk,G. Pals,R.R. Van Rijn,etc.Classification of Osteogenesis Imperfecta revisited[J].2010,53(1).
- [3]Shapiro JR,Thompson CB,Wu Y,etc.Bone mineral density and fracture rate in response to intravenous and oral bisphosphonates in adult osteogenesis imperfecta.[J].2010,87(2).
- [4]Cheung MS,Rauch F,Glorieux FH.Intravenous pamidronate in osteogenesis imperfecta type VII.[J].2009,84(3).
- [5]Brown JJ,Zacharin MR.Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.[J].2009,22(1).
- [6]Tavakkoli S,Salehpour S.Cyclic pamidronate therapy in children with osteogenesis imperfecta.[J].2010,23(1).
- [7]Peyman, Mottaghi.Intravenous bisphosphonates for postmenopausal osteoporosis.[J].2010,15.
- [8]Glorieux FH,Waltimo Siren J,Arponen H,etc.Cranial base abnormalities in osteogenesis imperfecta: phenotypic and genotypic determinants.[J].2011,26(2).
- [9]Pizones J,Bueno A,Fernandez Arroyo A,etc.Bone healing in children with osteogenesis imperfecta treated with bisphosphonates.[J].2005,25(3).
- [10]Bachrach LK,Ward LM.Clinical review 1: Bisphosphonate use in childhood osteoporosis.[J].2009,94(2).
- [11]Bas F,Gunoz H,Darendeliler F,etc.Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.[J].2008,28(4).
- [12]Sponsellor PD,Shapiro JR.Osteogenesis imperfecta: questions and answers.[J].2009,21(6).
- [13]Harrison R,Ahmed,Bishop N.A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.[J].2010,25(1).
- [14]Magnusson P,Eksborg S,Astrom E,etc.Biochemical bone markers in the assessment and pamidronate treatment of children and adolescents with osteogenesis imperfecta.[J].2010,99(12).
- [15]Kandemir N,Alikasifoglu A,Gonc N,etc.Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.[J].2008,21(1).
- [16]Das RR,Marwaha RK,Panigrahi I.Zolendronate in osteogenesis imperfecta.[J].2009,22(8).
- [17]Rauch F,Lalic L,Roughley P,etc.Relationship between genotype and skeletal phenotype in children and adolescents with osteogenesis imperfecta.[J].2010,25(6).
- [18]Li M,Xing XP,Zhang ZL,etc.Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.[J].2010,28(3).
- [19]Rajkumar SV.Zoledronic acid in myeloma: MRC Myeloma IX.[J].2010,376(9757).